Erythromycin Lactobionate Intravenous

Maa: Uusi-Seelanti

Kieli: englanti

Lähde: Medsafe (Medicines Safety Authority)

Aktiivinen ainesosa:

Erythromycin lactobionate 1000mg;  

Saatavilla:

Hospira NZ Ltd

INN (Kansainvälinen yleisnimi):

Erythromycin lactobionate 1000 mg

Annos:

1000 mg

Lääkemuoto:

Powder for injection

Koostumus:

Active: Erythromycin lactobionate 1000mg  

Kpl paketissa:

Vial, glass, 1 dose unit

luokka:

Prescription

Prescription tyyppi:

Prescription

Valmistaja:

Sandoz Industrial Products SpA

Tuoteyhteenveto:

Package - Contents - Shelf Life: Vial, glass, - 1 dose units - 24 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at or below 25°C 14 days reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, glass, single dose, 10 vials - 10 dose units - 24 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at or below 25°C 14 days reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Valtuutus päivämäärä:

1990-08-13

Valmisteyhteenveto

Data Sheet – New Zealand 

Hosp 1.0 
                 1 

ERYTHROMYCIN LACTOBIONATE INTRAVENOUS 

DESCRIPTION 
Erythromycin is a macrolide antibiotic produced by the growth of
certain strains of _Streptomyces _
_erythreus_. Erythromycin Lactobionate is produced
by the combination of erythromycin and lactobionic 
acid. 

PHARMACOLOGY 
The mode of action of erythromycin has been well characterised
as erythromycin binds to the ribosomes 
of bacteria to inhibit protein synthesis without
affecting nucleic acid synthesis. Erythromycin selectively 
binds only to the ribosomes of bacteria but not to the
cytoplasmic ribosomes of the host cells. This highly 
specific interaction of erythromycin with bacterial ribosomes is a
possible explanation for the low toxicity 
and exceptional clinical safety record of erythromycin. 

Erythromycin diffuses readily into most body fluids, except the
cerebrospinal fluid. However in cases of 
meningeal inflammation, higher concentrations are apparent. 

The apparent volume of distribution of erythromycin is around
45% of body weight in normal subjects. 
This large distribution volume is consistent with the extensive
tissue penetration of erythromycin. 

In the presence of normal hepatic function, erythromycin
is concentrated in the liver and excreted in the 
bile; the effect of hepatic dysfunction on excretion
of erythromycin by the liver is not known. 

Between 12% to 15% of intravenously administered erythromycin is
excreted in active form in the urine. 

The drug is also excreted in the faeces. 

The plasma elimination half-life in patients with normal renal
function is about 2 hours. In severe renal 
impairment the half-life may be prolonged to between 4 and 7 hours. 

MICROBIOLOGY: Erythromycin is bacteriostatic and bactericidal
depending on its concentration and the type 
of organism. It inhibits prote